United Therapeutics, which is based in Maryland and has a research and development office in RTP, has received FDA approval for an additional use of its Remodulin drug.

Remodulin can now be used intravenously, the company said. It had filed for the additional use 10 months ago.

The drug is used for pulmonary arterial hypertension.

For details, see: www.unither.com